EIF2AK3 and neoplasm: One-third of the patients treated with the highest dose of riluzole used in clinical practice (100 mg PO BID) for 14 days showed evidence of suppression of pERK and pAKT signaling in paired tumor biopsies and an associated decrease in metabolic activity on post-treatment PET-CT scans.